Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 320 participants.
Also called NCT03041259
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 320 participants
- Sponsor
- Reven Pharmaceuticals, Inc.
- Registry
-
NCT03041259
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT03041259. Randomized; single masking; primary purpose treatment. Start 2020-01 (anticipated); primary completion 2022-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction
- Acronym
- RESTORE
- Condition
- Critical Limb Ischemia
- Condition
- Peripheral Arterial Disease
- Intervention (Drug)
- Rejuveinix Low Dose
- Intervention (Drug)
- Rejuveinix High Dose
- Lead sponsor
- Reven Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct03041259- Content hash
016001483dd07516ed9c2b7853ee95dd1fbdb24e7c080813aa2a9eb1594e6df9